FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to oncology, and can be used for prediction of response to perioperative chemotherapy in stage II-III gastric cancer. DNA is recovered from patient’s venous blood leukocytes. A polymorphic variant of the CHEK2 Ile157Thr gene is determined using a polymerase chain reaction, followed by detection of amplification products by agarose gel electrophoresis. If observing carriage of heterozygous genotype Ile/Thr, a favourable response to perioperative chemotherapy in stage II-III gastric cancer is predicted.
EFFECT: method enables predicting the response to the perioperative chemotherapy according to the FLOT or XELOX regimen by determining the carriage of the heterozygous genotype Ile/Thr of the polymorphic variant Ile157Thr of the CHEK2 gene.
1 cl, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTING EFFECTIVENESS OF NEOADJUVANT CHEMORADIOTHERAPY IN RECTAL ADENOCARCINOMA | 2020 |
|
RU2732336C1 |
| METHOD FOR COMBINED TREATMENT OF OPERABLE STOMACH CANCER WITH A POSITIVE PDL STATUS | 2020 |
|
RU2756870C1 |
| METHOD FOR PREDICTION OF TIMOLOL TREATMENT EFFECTIVENESS OF PRIMARY OPEN-ANGLE GLAUCOMA | 2018 |
|
RU2694744C1 |
| METHOD OF COMBINED TREATMENT OF LOCALLY ADVANCED GASTRIC CANCER | 2020 |
|
RU2725079C2 |
| METHOD FOR ASSESSING PRIMARY RESPONSE TO COMBINED CHEMOTHERAPY OF SPORADIC OVARIAN CANCER OF STAGES III AND IV | 2021 |
|
RU2769543C2 |
| METHOD OF PREDICTING RISK OF INFECTIOUS ENDOCARDITIS DEVELOPMENT | 2015 |
|
RU2617060C1 |
| METHODS AND COMPOSITIONS FOR PREDICTION OF THERAPEUTIC EFFICIENCY OF TREATMENT OF ONCOLOGICAL DISEASES AND PREDICTION OF ONCOLOGICAL DISEASES | 2016 |
|
RU2785291C2 |
| METHOD FOR DETERMINING THE GENETIC PREDISPOSITION TO THE DEVELOPMENT OF MULTIDRUG-RESISTANT TUBERCULOSIS MYCOBACTERIUM TUBERCULOSIS IN HIV INFECTION | 2020 |
|
RU2750715C1 |
| METHOD FOR DETERMINATION OF GENETIC PREDISPOSITION TO INFECTIVE ENDOCARDITIS | 2016 |
|
RU2618459C1 |
| METHOD FOR PREDICTION OF CISPLATIN TREATMENT EFFICACY IN MALIGNANT DISEASE | 2014 |
|
RU2582968C2 |
